Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Aug 12, 2013

The 20 Top Paid Women Executives in Biopharma

Who are the highest-paid females in the industry this year?

The 20 Top Paid Women Executives in Biopharma

See how well these 20 sisters are doin’ it for themselves. [© stefa_neve - Fotolia.com]

  • #10. Jacqualyn A. Fouse, Ph.D.

    Company: Celgene

    Title: EVP and CFO

    2012 Compensation: $3,450,103

    2011 Compensation: $2,535,033

    % Change: 36.1%

  • #9. Robin L. Washington

    Company: Gilead Sciences

    Title: SVP and CFO

    2012 Compensation: $4,175,593

    2011 Compensation: $4,032,193

    % Change: 3.6%

  • #8. Sandra Peterson

    Company: Johnson & Johnson

    Title: Group Worldwide Chair

    2012 Compensation: $4,698,8506

    2011 Compensation: N/A6

    % Change: N/A6

  • #7. Silvia Ayyoubi

    Company: Roche

    Title: Head, Group Human Resources

    2012 Compensation: $5,346,932 (CHF 4,970,897)1

    2011 Compensation: $4,342,348 (CHF 4,037,074)1,7

    % Change: 23.1%

  • #6. Amy W. Schulman

    Company: Pfizer

    Title: EVP and General Counsel; Business Unit Lead, Consumer Healthcare

    2012 Compensation: $5,573,218

    2011 Compensation: $5,764,662

    % Change: -3.3%

  • #5. Sandra Leung

    Company: Bristol-Myers Squibb

    Title: General Counsel & Corporate Secretary

    2012 Compensation: $5,892,772

    2011 Compensation: $5,491,673

    % Change: 7.3%

  • #4. Martine Rothblatt

    Company: United Therapeutics

    Title: CEO

    2012 Compensation: $7,958,328

    2011 Compensation: $3,161,350

    % Change: 151.7%

  • #3. Heather Bresch

    Company: Mylan

    Title: CEO

    2012 Compensation: $8,000,628

    2011 Compensation: $9,208,0348

    % Change: -13.1%

  • #2. Beatrice Cazala

    Company: Bristol-Myers Squibb

    Title: EVP, Commercial Operations

    2012 Compensation: $8,031,025

    2011 Compensation: $5,941,1679

    % Change: 35.2%

  • #1. Laura J. Schumacher

    Company: AbbVie

    Title: EVP, Business Development, External Affairs and General Counsel

    2012 Compensation: $10,192,74810

    2011 Compensation: $5,567,49310

    % Change: 83.1%



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »